Received Aug 17, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (PFIZER-BIONTECH)) | PFIZER\BIONTECH | 1 | ME6072 | SYR / RA |
Adverse Event(s): ? On July 31, 2025, developed chest pain, shortness of breath, and elevated heart rate within 1?2 days after receiving the COVID-19 vaccine. ? Diagnosed with pericarditis on August 1, 2025. ? Symptoms included chest discomfort, fatigue, lightheadedness, and elevated heart rate reaching the 120s?130s with light activity (walking, climbing stairs). ? Blood pressure has occasionally been low Treatment: ? Initially prescribed ibuprofen 800 mg three times daily for 10 days. ? Due to persistent inflammation, started on colchicine as ongoing treatment, as well as continued ibuprofen for three additional weeks. ? Advised to avoid strenuous activity, monitor heart rate, and rest. ? Scheduled for a follow-up with cardiology on August 25, 2025. Outcome (as of submission): ? Symptoms are gradually improving but not fully resolved. ? Still experiencing elevated heart rate with exertion and occasional fatigue. ? Continuing colchicine therapy and activity modification per physician guidance. ? Concern for possible recurrence or chronic pericarditis remains.
N/A
N/A
N/A
N/A
August 1, 2025: Emergency evaluation following onset of chest pain and shortness of breath. ? Electrocardiogram (ECG/EKG): Findings consistent with pericarditis (abnormal ST/T wave changes). ? Chest exam: Confirmed inflammation. ? Blood work: Elevated inflammatory markers (exact values not provided to patient). ? Diagnosis: Pericarditis.